臍帯血幹細胞の世界市場2020–2027:保管サービス別(公的臍帯血バンク、私的臍帯血バンク、ハイブリッド臍帯血バンク)、治療薬別、用途別

◆英語タイトル:Stem Cell Umbilical Cord Blood Market by Storage Service (Public Cord Blood Banks, Private Cord Blood Banks, and Hybrid Cord Blood Banks), Therapeutics (Cancer, Diabetes, Blood Diseases, Immune Disorders, Metabolic Disorders, and Other Diseases), and Application( Transplant Medicine and Regenerative Medicine): Global Opportunity Analysis and Industry Forecast, 2020–2027
◆商品コード:AMR20OC037
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2020年8月
◆ページ数:209
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,769 ⇒換算¥623,052見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥696,600見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥971,460見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、臍帯血幹細胞の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、保管サービス別分析(公的臍帯血バンク、私的臍帯血バンク、ハイブリッド臍帯血バンク)、治療薬別分析(癌、糖尿病、造血系、免疫障害、代謝障害)、用途別分析(移植医療、再生医療)、地域別分析情報、競争状況、企業情報など、以下の構成でまとめております。
・イントロダクション
・エグゼクティブサマリー
・市場動向
・臍帯血幹細胞の世界市場規模:保管サービス別(公的臍帯血バンク、私的臍帯血バンク、ハイブリッド臍帯血バンク)
・臍帯血幹細胞の世界市場規模:治療薬別(癌、糖尿病、造血系、免疫障害、代謝障害)
・臍帯血幹細胞の世界市場規模:用途別(移植医療、再生医療)
・臍帯血幹細胞の世界市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

The global stem cell umbilical cord blood market was valued at $3,110.8 million in 2019, and is projected to reach $10,135.20 million by 2027, registering a CAGR of 16.9% from 2020 to 2027.
Presently, the global stem cell market dominates the healthcare industry with its reliable and cost-effective methods of treatment and fewer side effects. The umbilical cord blood stem cell segment is one of the potential segments of the stem cell market, which is projected to grow in the future. Cord blood is one of the rich sources of stem cells, which are treated as waste after pregnancy or childbirth; however, this blood has huge potential to treat chronic diseases such as cancer, diabetes, and blood disease immune diseases.

Currently, more than 80 genetic diseases can be treated with cord blood and the blood is rich source of hematopoietic stem cells. Various governments are supporting the research and clinical trials of cord blood stem cells, which is has increased the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. However, competition in the market is intense with companies trying to create brand awareness, therefore, compelling market players to adopt many market-based strategies. These stem cells are the only type of cells that are stored in controlled conditions due to their lower volume and higher cell count.
Cost structure of the stem cell treatment has a major impact on the growth of the market in developed countries. Stem cells collected from cord blood are used in treatment of many rare diseases that include metabolic diseases and immune diseases. The overall stem cell umbilical cord blood market is growing from clinical applications to commercialization. Companies involved in the research and commercialization of stem cell therapies are adopting approval and clinical trials as their primary strategy and product launch as their secondary strategy.

Based on the storage services, the market is segmented into private cord blood banks, public cord blood banks and hybrid cord blood banks. The private cord banks segment was the highest contributor to the market, with $1,537 million in 2019, and is estimated to reach $4,765.90 million by 2027, at a CAGR of 15.3% during the forecast period.
Based on therapeutics, the market is categorized into Cancer, Diabetes, Blood diseases, Immune disorders, Metabolic disorders and other diseases. The diabetes segment was the highest contributor to the market, with $794 million in 2019, and is estimated to reach $2,655.58 million by 2027, at a CAGR of 16.4% during the forecast period.
Based on application, the market is categorized into transplant medicine and regenerative medicine. The regenerative medicine segment was the highest contributor to the market, with $1,854.12 million in 2019, and is estimated to reach $5,878.55 million by 2027, at a CAGR of 15.6% during the forecast period.
The stem cell umbilical cord blood market is more lucrative in North America and European countries. Most patents granted for cord blood were from the U.S. and European authorities. North America shared the largest revenue of $1,353.20 million in 2019, however Asia-Pacific is expected to grow at CAGR of 16.7% CAGR during the forecast period.
The companies offering stem cell umbilical cord blood storage services include Cordlife Group Limited, Cord Blood America, Cryo-Cell International, Medipost, Global Cord Blood Corporation, Americord Registry, and Cordvida.

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current stem cell umbilical cord blood trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
• The market forecast is studied from 2020 to 2027.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS
By Storage services
• Public Cord Blood Banks
• Private Cord Blood Banks
• Hybrid Cord Blood Banks

By Therapeutics
• Cancer
• Diabetes
• Blood Diseases
• Immune Disorders
• Metabolic Disorders
• Other Diseases

By Application
• Transplant Medicine
• Regenerative Medicine

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA

• Key players in the market
o Cordlife Group Limited
o Cord Blood America
o Cryo-Cell International
o Medipost
o Americord Registry
o Esperite
o China Cord Blood Corporation
o LifeCell Inetrnational
o ViaCord
o Vita34 AG

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Research methodology

1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.1.1.Drivers

3.1.1.1.Diversification of services
3.1.1.2.Genetic testing, fertility, and reproduction assisted services
3.1.1.3.Treatment for chronic diseases
3.1.1.4.Rise in spending capacity and suitable payment plans

3.1.2.Restraints

3.1.2.1.Legal and ethical issues during collection
3.1.2.2.Higher cost of therapies
3.1.2.3.Unavailability of suitable matched donor

3.1.3.Opportunities

3.1.3.1.Advancements in therapeutic applications
3.1.3.2.Rise in funds for public storage

3.1.4.Value chain analysis of stem cell umbilical cord blood market

3.2.Top Player Positioning, 2019

CHAPTER 4:STEM CELL UMBILICAL CORD BLOOD MARKET, BY STORAGE SERIVCES

4.1.Overview

4.1.1.Market size and forecast

4.2.Public Cord Blood Banks

4.2.1.Overview
4.2.2.Key growth trends and opportunities
4.2.3.Market size and forecast
4.2.4.Market analysis, by country

4.3.Private Cord Blood Banks

4.3.1.Overview
4.3.2.Key growth trends and opportunities
4.3.3.Market size and forecast
4.3.4.Market analysis, by country

4.4.Hybrid Cord Blood Banks

4.4.1.Overview
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:STEM CELL UMBILICAL CORD BLOOD MARKET, BY THERAPEUTICS

5.1.Overview

5.1.1.Market size and forecast

5.2.Cancer

5.2.1.Overview
5.2.2.Market size and forecast
5.2.3.Market analysis, by country

5.3.Diabetes

5.3.1.Overview
5.3.2.Market size and forecast
5.3.3.Market analysis, by country

5.4.Blood diseases

5.4.1.Overview
5.4.2.Market size and forecast
5.4.3.Market analysis, by country

5.5.Immune Disorders

5.5.1.Overview
5.5.2.Market size and forecast
5.5.3.Market analysis, by country

5.6.Metabolic Disorders

5.6.1.Overview
5.6.2.Market size and forecast
5.6.3.Market analysis, by country

5.7.Others

5.7.1.Overview
5.7.2.Market size and forecast
5.7.3.Market analysis, by country

CHAPTER 6:STEM CELL UMBILICAL CORD BLOOD MARKET, BY APPLICATION

6.1.Overview

6.1.1.Market size and forecast

6.2.Transplant Medicine

6.2.1.Overview
6.2.2.Market size and forecast
6.2.3.Market analysis, by country

6.3.Regenerative Medicine

6.3.1.Overview
6.3.2.Market size and forecast
6.3.3.Market analysis, by country

CHAPTER 7:STEM CELL UMBILICAL CORD BLOOD MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by storage service
7.2.4.Market size and forecast, by therapeutics
7.2.5.Market size and forecast, by application
7.2.6.U.S.

7.2.6.1.U.S. market size and forecast, by storage service
7.2.6.2.U.S. market size and forecast, by therapeutics
7.2.6.3.U.S. market size and forecast, by application

7.2.7.Canada

7.2.7.1.Canada market size and forecast, by storage service
7.2.7.2.Canada market size and forecast, by therapeutics
7.2.7.3.Canada market size and forecast, by application

7.2.8.Mexico

7.2.8.1.Mexico market size and forecast, by storage service
7.2.8.2.Mexico market size and forecast, by therapeutics
7.2.8.3.Mexico market size and forecast, by application

7.3.Europe

7.3.1.Europe market size and forecast, by country
7.3.2.Europe market size and forecast, by storage service
7.3.3.Europe market size and forecast, by therapeutics
7.3.4.Europe market size and forecast, by application
7.3.5.UK

7.3.5.1.UK market size and forecast, by storage service
7.3.5.2.UK market size and forecast, by therapeutics
7.3.5.3.UK market size and forecast, by application

7.3.6.France

7.3.6.1.France market size and forecast, by storage service
7.3.6.2.France market size and forecast, by storage service
7.3.6.3.France market size and forecast, by therapeutics
7.3.6.4.France market size and forecast, by application

7.3.7.Germany

7.3.7.1.Germany market size and forecast, by storage service
7.3.7.2.Germany market size and forecast, by therapeutics
7.3.7.3.Germany market size and forecast, by application

7.3.8.Italy

7.3.8.1.Italy market size and forecast, by storage service
7.3.8.2.Italy market size and forecast, by therapeutics
7.3.8.3.Italy market size and forecast, by application

7.3.9.Spain

7.3.9.1.Spain market size and forecast, by storage service
7.3.9.2.Spain market size and forecast, by therapeutics
7.3.9.3.Spain market size and forecast, by application

7.3.10.Rest of Europe

7.3.10.1.Rest of Europe market size and forecast, by storage service
7.3.10.2.Rest of Europe market size and forecast, by therapeutics
7.3.10.3.Rest of Europe market size and forecast, by application

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities
7.4.2.Asia-Pacific market size and forecast, by country
7.4.3.Asia-Pacific market size and forecast, by storage service
7.4.4.Asia-Pacific market size and forecast, by therapeutics
7.4.5.Asia-Pacific market size and forecast, by application
7.4.6.Japan

7.4.6.1.Japan market size and forecast, by storage service
7.4.6.2.Japan market size and forecast, by therapeutics
7.4.6.3.Japan market size and forecast, by application

7.4.7.China

7.4.7.1.China market size and forecast, by storage service
7.4.7.2.China market size and forecast, by therapeutics
7.4.7.3.China market size and forecast, by application

7.4.8.India

7.4.8.1.India market size and forecast, by storage service
7.4.8.2.India market size and forecast, by therapeutics
7.4.8.3.India market size and forecast, by application

7.4.9.Rest of Asia-Pacific

7.4.9.1.Rest of Asia-Pacific market size and forecast, by storage service
7.4.9.2.Rest of Asia-Pacific market size and forecast, by therapeutics
7.4.9.3.Rest of Asia-Pacific market size and forecast, by application

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.LAMEA market size and forecast, by country
7.5.3.LAMEA market size and forecast, by storage service
7.5.4.LAMEA market size and forecast, by therapeutics
7.5.5.LAMEA market size and forecast, by application
7.5.6.Brazil

7.5.6.1.Brazil market size and forecast, by storage service
7.5.6.2.Brazil market size and forecast, by therapeutics
7.5.6.3.Brazil market size and forecast, by application

7.5.7.South Africa

7.5.7.1.South Africa market size and forecast, by storage service
7.5.7.2.South Africa market size and forecast, by therapeutics
7.5.7.3.South Africa market size and forecast, by application

7.5.8.Saudi Arabia

7.5.8.1.Saudi Arabia market size and forecast, by storage service
7.5.8.2.Saudi Arabia market size and forecast, by therapeutics
7.5.8.3.Saudi Arabia market size and forecast, by application

7.5.9.Rest of LAMEA

7.5.9.1.Rest of LAMEA market size and forecast, by storage service
7.5.9.2.Rest of LAMEA market size and forecast, by therapeutics
7.5.9.3.Rest of LAMEA market size and forecast, by application

CHAPTER 8:COMPANY PROFILES

8.1.Americord Registry LLC

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio

8.2.China Cord Blood Corporation

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Business performance

8.3.Cord Blood America, Inc.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments

8.4.Cordlife Group Limited

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.Cryo-Cell International, Inc.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.Esperite N.V.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio

8.7.LifeCell International Pvt. Ltd.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio

8.8.Medipost Co. Ltd.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.ViaCord

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio

8.10.Vita34 AG

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 02.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY PUBLIC CORD BLOOD STORAGE, 2019–2027 ($MILLION)
TABLE 03.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY PRIVATE CORD BLOOD STORAGE, 2019–2027 ($MILLION)
TABLE 04.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY HYBRID CORD BLOOD STORAGE, 2019–2027 ($MILLION)
TABLE 05.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS , 2019–2027 ($MILLION)
TABLE 06.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR CANCER , 2019–2027 ($MILLION)
TABLE 07.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR DIABETES 2019–2027 ($MILLION)
TABLE 08.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 09.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR IMMUNE DISORDERS, 2019–2027 ($MILLION)
TABLE 10.STEM CELL UMBILICIAL CORD BLOOD MARKET FOR METABOLIC DISORDERS, 2019–2027 ($MILLION)
TABLE 11.GLOBAL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY TYPE OF IMMUNE DISORDERS, 2019–2027 ($MILLION)
TABLE 12.GLOBAL STEM CELL UMBILICIAL CORD BLOOD MARKET FOR OTHERS 2019–2027 ($MILLION)
TABLE 13.STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 14.STEM CELL UMBILICIAL CORD BLOOD MARKET, FOR TRANSPLANT MEDICINE , 2019–2027 ($MILLION)
TABLE 15.STEM CELL UMBILICIAL CORD BLOOD MARKET, FOR REGENERATIVE MEDICINE , 2019–2027 ($MILLION)
TABLE 16.STEM CELL UMBLICIAL CORD BLOOD MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 17.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019 –2026 ($MILLION)
TABLE 18.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 19.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2026 ($MILLION)
TABLE 20.NORTH AMERICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 21.U.S. STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 22.U.S. STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2026 ($MILLION)
TABLE 23.U.S. STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 24.CANADA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 25.CANADA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 26.CANADA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 27.MEXICO STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 28.MEXICO STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 29.MEXICO STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 30.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 31.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 32.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 33.EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 34.UK STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 35.UK STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2020 ($MILLION)
TABLE 36.UK STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 37.FRANCE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 38.FRANCE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 39.FRANCE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 40.GERMANY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 41.GERMANY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019S–2027 ($MILLION)
TABLE 42.GERMANY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 43.ITALY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 44.ITALY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 45.ITALY STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 46.SPAIN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 47.SPAIN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 48.SPAIN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 49.REST OF EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 50.REST OF EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 51.REST OF EUROPE STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 52.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 53.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 54.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 55.ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 56.JAPAN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 57.JAPAN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 58.JAPAN STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 59.CHINA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 60.CHINA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 61.CHINA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 62.INDIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 63.INDIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 64.INDIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 65.REST OF ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 68.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 69.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 70.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 71.LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 72.BRAZIL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 73.BRAZIL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 74.BRAZIL STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 75.SOUTH AFRICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 76.SOUTH AFRICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 77.SOUTH AFRICA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 78.SAUDI ARABIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 79.SAUDI ARABIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 80.SAUDI ARABIA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 81.REST OF LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY STORAGE SERVICE, 2019–2027 ($MILLION)
TABLE 82.REST OF LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY THERAPEUTICS, 2019–2027 ($MILLION)
TABLE 83.REST OF LAMEA STEM CELL UMBILICIAL CORD BLOOD MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 84.AMERICORD REGISTRY LLC: COMPANY SNAPSHOT
TABLE 85.AMERICORD: OPERATING SEGMENTS
TABLE 86.CRYO-CELL INTERNATIONALS: PRODUCT PORTFOLIO
TABLE 87.CHINA CORD BLOOD CORPORATION: COMPANY SNAPSHOT
TABLE 88.CHINA CORD BLOOD CORPORATION: OPERATING SEGMENTS
TABLE 89.CORD BLOOD AMERICA: COMPANY SNAPSHOT
TABLE 90.CORD BLOOD AMERICA: OPERATING SEGMENTS
TABLE 91.CORDLIFE GROUP LIMITED: COMPANY SNAPSHOT
TABLE 92.CORDLIFE GROUP LIMITED: OPERATING SEGMENTS
TABLE 93.CORDLIFE: PRODUCT PORTFOLIO
TABLE 94.CORDLIFE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 95.CRYO-CELL INTERNATIONAL INC.: COMPANY SNAPSHOT
TABLE 96.CRYO-CELL INTERNATIONALS: OPERATING SEGMENTS
TABLE 97.CRYO-CELL INTERNATIONALS OFFERS FOLLOWING SERVICES:CRYO-CELL INTERNATIONALS: PRODUCT PORTFOLIO
TABLE 98.ESPERITE: COMPANY SNAPSHOT
TABLE 99.ESPERITE: OPERATING SEGMENTS
TABLE 100.ESPERITE : PRODUCT PORTFOLIO
TABLE 01.LIFECELL: COMPANY SNAPSHOT
TABLE 02.LIFECELL: OPERATING SEGMENTS
TABLE 03.LIFECELL: PRODUCT PORTFOLIO
TABLE 04.MEDIPOST CO. LTD: COMPANY SNAPSHOT
TABLE 05.MEDIPOST CO. LTD: OPERATING SEGMENTS
TABLE 06.MEDIPOST CO. LTD: PRODUCT PORTFOLIO
TABLE 07.MEDIPOST CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 01.VIACORD : COMPANY SNAPSHOT
TABLE 02.VITA34 INTERNATIONAL: OPERATING SEGMENTS
TABLE 03.VIACORD: PRODUCT PORTFOLIO
TABLE 04.VITA34 INTERNATIONAL: COMPANY SNAPSHOT
TABLE 05.VITA34 INTERNATIONAL: OPERATING SEGMENTS
TABLE 06.VITA34 INTERNATIONAL: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.TOP PLAYER POSITIONING, 2019
FIGURE 02.COMPARATIVE SHARE ANALYSIS FOR PUBLIC CORD BLOOD BANKS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 03.COMPARATIVE SHARE ANALYSIS OF PRIVATE CORD BLOOD BANKS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 04.COMPARATIVE SHARE ANALYSIS OF HYBRID CORD BLOOD BANKS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 05.COMPARATIVE SHARE ANALYSIS OF CANCER MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 06.COMPARATIVE SHARE ANALYSIS OF DIABETES MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 07.COMPARATIVE SHARE ANALYSIS OF BLOOD DISEASES MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 08.COMPARATIVE SHARE ANALYSIS OF IMMUNE DISORDERS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 09.COMPARATIVE SHARE ANALYSIS OF METABOLIC DISORDERS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 10.COMPARATIVE SHARE ANALYSIS OF OTHERS MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 11.COMPARATIVE SHARE ANALYSIS OF TRANSPLANT MEDICINE MARKET BY COUNTRY, 2019 & 2027 (%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF REGENERATIVE MEDICINE MARKET BY COUNTRY, 2019 & 2027 (%)

CHINA CORD BLOOD CORPORATION: NET SALES, 2017–2019 ($MILLION)

CORDLIFE GROUP LIMITED: NET SALES, 2017–2018 ($MILLION)
CORDLIFE: REVENUE SHARE BY SEGMENT, 2018 (%)
CRYO-CELL INTERNATIONAL: NET SALES, 2016–2018 ($MILLION)
CRYO CELL INTERNATIONALS: REVENUE SHARE BY SEGMENTS, 2018 (%)
MEDIPOST CO. LTD: NET SALES, 2017–2018 ($MILLION)
VITA34 INTERNATIONAL: NET SALES, 2017–2018 ($MILLION)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[臍帯血幹細胞の世界市場2020–2027:保管サービス別(公的臍帯血バンク、私的臍帯血バンク、ハイブリッド臍帯血バンク)、治療薬別、用途別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆